Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease

David M. Holtzman(Eli Lilly (United States)), Kelly R. Bales(Eli Lilly (United States)), Tanya Tenkova(Eli Lilly (United States)), Anne M. Fagan(Eli Lilly (United States)), Maia Parsadanian(Eli Lilly (United States)), Leah Sartorius(Eli Lilly (United States)), Brian Mackey(Eli Lilly (United States)), John W. Olney(Eli Lilly (United States)), Daniel W. McKeel(Eli Lilly (United States)), David F. Wozniak(Eli Lilly (United States)), Steven M. Paul(Eli Lilly (United States))
Proceedings of the National Academy of Sciences
February 29, 2000
Cited by 943

Abstract

Apolipoprotein E (apoE) alleles determine the age-adjusted relative risk (epsilon4 > epsilon3) for Alzheimer's disease (AD). ApoE may affect AD pathogenesis by promoting deposition of the amyloid-beta (Abeta) peptide and its conversion to a fibrillar form. To determine the effect of apoE on Abeta deposition and AD pathology, we compared APP(V717F) transgenic (TG) mice expressing mouse, human, or no apoE (apoE(-/-)). A severe, plaque-associated neuritic dystrophy developed in APP(V717F) TG mice expressing mouse or human apoE. Though significant levels of Abeta deposition also occurred in APP(V717F) TG, apoE(-/-) mice, neuritic degeneration was virtually absent. Expression of apoE3 and apoE4 in APP(V717F) TG, apoE(-/-) mice resulted in fibrillar Abeta deposits and neuritic plaques by 15 months of age and substantially (>10-fold) more fibrillar deposits were observed in apoE4-expressing APP(V717F) TG mice. Our data demonstrate a critical and isoform-specific role for apoE in neuritic plaque formation, a pathological hallmark of AD.


Related Papers

No related papers found

Powered by citation graph analysis